ADHD "Experts" Conflicts of Interest
"It is difficult to get a man to understand something when his salary depends upon his not understanding it." Upton Beall Sinclair Jr.
This alphabetical list below includes the:
World's top 66 'ADHD experts' identified by Expertscape as having authored or co-authored the most influential publications on ADHD from 2011 to 2021.
Self-described ADHD ‘world experts’ who signed The World Federation of ADHD 2021 Consensus Statement.
Other prominent 'ADHD experts'.
It only lists some of their relationships with business involved in the manufacturing and/or marketing of ADHD drugs. It does not include ties to other commercial organisations involved in the ADHD Industry or many other Big Pharma financial relationships.
L Eugene Arnold (USA 106 articles ADHD Expert World Ranking 9) - Eli Lilly, Neuropharm, Novartis, Noven, Shire, Otsuka, Pfizer, Roche and Tris and Astrazeneca, Biomarin, Curemark, Noven, Seaside Therapeutics X and Celgene, Eli Lilly, Targacept, Sigma Tau, Organon, Abbott, McNeil X.
Martjin Arns Germany (ADHD Expert World Ranking 32) - Has done extensive research into neuro-biofeedback and ADHD and has declared commercial ties in regard to the commercialisation of nuero-biofeedback.
Tobias Banaschewski # Germany (ADHD Expert World Ranking 5) - Lundbeck, Shire/Takeda and Janssen, McNeil, Eli Lilly, Novartis, Shire X and Medice, Neurim Pharmaceuticals, Oberberg GmbH, Infectopharm X.
Russel Barkley - Eli Lilly, Shire, McNeil and Medice* and Janssen-Cilag, Novartis* and Theravance*. Note: Barkley was the lead author of the 2002 International Consensus Statement on ADHD that offered no collaborating evidence (not a single academic reference) and did not declare the extensive conflict of interest of the signatories but concluded that claims that “ADHD is a fictitious disorder… is tantamount to declaring the earth flat, the laws of gravity debatable, and the periodic table in chemistry a fraud”. Barkley et al were criticised by a group of psychiatrist and scientists (led by Professor Sami Timmimi) as attempting to stifle legitimate and needed debate about ADHD.
Stephen P. Becker USA (ADHD Expert World Ranking 11) No direct financial ties to ADHD drug manufacturers found. He has received grant funding from various U.S. institutions including the Institute of Education Sciences, U.S. Department of Education; National Institute of Mental Health and Cincinnati Children’s Research Foundation.
Joseph Biederman # USA (ADHD Expert World Ranking 12) - Pfizer, Sunovion, Takeda/Shire, Tris, Shire, Sunovion, Theravance; Lundbeck and Johnson and Johnson, Eli Lilly and Co., Janssen, McNeil, Otsuka, Shire, Janssen, McNeil, Novartis, Shire, UCB Pharma, Inc. GlaxoSmithKline, Novartis, Pfizer X. and Alcobra, Genentech, Ironshore, Magceutics, Merck, Neurocentria, Roche, Aevi Genomics, Akili, Alcobra, Arbor Pharmaceuticals, Jazz Pharma, Medgenics, Piper Jaffray, the American Professional Society of ADHD and Related Disorders, he has a financial interest in Avekshan, a company that develops treatments for ADHD and has received royalties from a copyrighted rating scale used for ADHD diagnoses X. Note: Biederman was previously sanctioned by Harvard for not properly disclosing payments received from multiple drug companies. (Read More)
Daniel Brandeis Austria (ADHD Expert World Ranking 23) - No direct ADHD drug company ties found however he along with many researchers with extensive ADHD drug company connections participated in research into non-pharmaceutical treatments on ADHD that was supported by Janssen-Cilag, Lilly, Medice, Shire, and Vifor.
Jan K. Buitelaar # Netherlands (ADHD Expert World Ranking 3) - Takeda/Shire, Janssen and Eli Lilly, Lundbeck, Shire, Novartis* and Bristol-Myer Squibb, UCB X. and Medice, Roche, Angelini, and Servier X.
Ann C Childress USA (ADHD Expert World Ranking 17) Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Ironshore, Johnson & Johnson, Eli Lilly, Novartis, Ortho-McNeil, Janssen, Rhodes, Shire, Sunovion, Theravance, and Pfizer.
Keith Conners USA - Celgene, Shire, Noven, Eli Lilly, Targacept, Novartis, Shire, Novartis, Alza, Noven, Eli Lilly, McNeil. Note: Late in life Connors (now deceased) who has been described as the Father of ADHD (and devised the Connors Rating Scale which is commonly used to diagnose ADHD) declared to colleagues that the over-diagnosis of ADHD was “an epidemic of tragic proportions.”
Stacey Espinet # signed the Consensus Statement on behalf of Canadian ADHD Resource Alliance - None Declared in the WFADHD Consensus Statement however CADDRA receives funding from pharmaceutical companies X.
Stephen V. Faraone (# First Signatory of the WFADHD Consensus Statement on ADHD and President of WFADHD) USA (ADHD Expert World Ranking 1) - Arbor, Ironshore, Ondosis, Otsuka, Rhodes, Shire/Takeda, Sunovion, Supernus, Tris, and Vallon. Alcobra, Eli Lilly, Enzymotec, Janssen, KemPharm, Lundbeck/Takeda, McNeil, Neurolifesciences, Neurovance, Novartis and Pfizer and Akili Interactive Labs, Genomind, Ironshore, Medice X.
Robert Findling USA (ADHD Expert World Ranking 47) - Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Cypress Biosciences, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Shire, Solvay, Supernus, Wyeth.
Laurence L Greenhill USA - Eli Lilly, Novartis, McNeil, Otsuka, Pfizer, Janzen-Cilag, Johnson and Johnson and Bristol-Myers Squibb, GlaxoSmithKline*. and Shire, Cephalon, Celltech, Sanofi, Aventis, Otsuka, Janssen.
Chris Hollis # UK - No connections declared in the WFADHD Consensus Statement however she along with many researchers with extensive ADHD drug company connections participated in research into non-pharmaceutical treatments on ADHD that was supported by Janssen-Cilag, Lilly, Medice, Shire, and Vifor.
J.J. Sandra Kooij # Netherlands (ADHD Expert World Ranking 51) - Receives research support from Parnassia Groep, the Netherlands it is not known if this organisation is sponsored by ADHD drug manufacturers.
Jeffrey H. Newcorn # USA (ADHD Expert World Ranking 44) - Arbor, Lundbeck, OnDosis, Rhodes, Shire/Takeda, Pfizer and Sunovion, Otsuka, Medice, Shire and NeuroLifeSciences, Rhodes Pharmaceuticals X and Eli Lilly, Alza, Celgene, McNeil, Celltech/UCB, Novartis, Sanofi Aventis, Janssen, and Bristol-Myers Squibb X.
Joel T. Nigg # USA (ADHD Expert World Ranking 14) - None Declared in the WFADHD Consensus Statement. He has previously declared receiving payment for consulting to the TOVA Company and to an organisation funded by Shire.
William Pelham USA (ADHD Expert World Ranking 30) - Abbott Laboratories and Alza, Shire, Noven, Eli Lilly, Cephalon, McNeil, Richwood, Noven, Novartis, Celgene, and Abbott. Note: Professor Pelham deserves credit for his honesty in regards to his assessment of the long term outcomes associated with the use of ADHD medications demonstrated in the Multimodal Treatment Study of Children with ADHD (commonly referred to as the MTA Study). For details read https://www.theguardian.com/news/2007/nov/12/uknews.health
J. Antoni Ramos-Quiroga # Spain (ADHD Expert World Ranking 20) - Eli-Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Lundbeck, Medice and Almirall, Braingaze, Sincrolab, and Rubió, Actelion, Ferrer, and Rubió X and Shionogui, Bial, Psious, Roche X.
Kapil Sayal UK (ADHD Expert World Ranking 62) - No direct ADHD drug company ties found. Note: Sayal led some excellent research that showed that the youngest children in classrooms in Finland are at much higher risk of being diagnosed and ‘medicated’ for ADHD than their older classmates. Later research led by the ADHDisBS.com editor Dr Martin Whitely demonstrated this is a global phenomenon.
Thomas Spencer USA (ADHD Expert World Ranking 55) - Cephalon, Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Novartis, Pfizer, Shire and Alcobra, Avekshan, Ironshore, Lundbeck, Sunovion, Dr. Spencer received research support from Royalties and Licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing and has a U.S. Patent for a non-stimulant treatment for ADHD. Note: Wilens was previously sanctioned by Harvard for not properly disclosing payments received from multiple drug companies. (Read More)
Hans-Christoph Steinhausen # Denmark - None Declared in the WFADHD Consensus Statement but has commercial ties to Medice X and Janssen-Cilag, Eli Lilly, Novartis, Shire, and UCB X.
Anita Thapar # UK (ADHD Expert World Ranking 18) - None Declared in the WFADHD Consensus Statement. Note: For a critique of an appalling overhyped claim by Thapar as having proved “that ADHD is a genetic disease” read ADHD: How a Lie ‘Medicated’ Often Enough Became the Truth.
Saskia Van der Oord # Germany (ADHD Expert World Ranking 65) - No connections declared in the WFADHD Consensus Statement however she along with many researchers with extensive ADHD drug company connections participated in research into non-pharmaceutical treatments on ADHD that was supported by Janssen-Cilag, Lilly, Medice, Shire, and Vifor.
Timothy Wilens USA (ADHD Expert World Ranking 45) - Abbott, Cephalon, Ortho-McNeil, Eli Lilly and Company, Shire, Novartis Pharmaceuticals, Janssen, Pfizer and Alcobra, Neurovance/Otsuka, and Ironshore*. Note: Wilens was previously sanctioned by Harvard for not properly disclosing payments received from multiple drug companies. (Read More)
# Indicates this ‘expert’ is a signatory of The World Federation of ADHD International Consensus Statement.
X indicates that the ‘expert’ is a signatory to the The World Federation of ADHD International Consensus Statement but did not declare the preceding ADHD drug manufacturer financial relationship in the statement.
The world's ten most influential 'ADHD experts' all take funds from multiple ADHD drug manufacturers. Topping the list is American psychologist Prof Stephen V. Faraone who has commercial ties to 21 ADHD drug companies.
Despite the success of the Industry in medicalising childhood behaviours, the argument that ‘ADHD is a medical condition’ doesn’t stack-up. A far more plausible explanation is that ADHD is an Industry, motivated to maximise profits, just like any other industry. In fact, with US$22,500,000,000 in annual drug sales, and countless other billions received for diagnosing and promoting the ‘disorder’, it is ridiculous to argue that ADHD is not an Industry.